National Clinical Trials Network Groups News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Merck s KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) as Adjuvant Therapy Versus Observation in High-Risk Patients With Localized Muscle-Invasive and Locally Advanced Urothelial Carcinoma After Surgery -January 26, 2024 at 10:01 am EST

KEYTRUDA doubled median DFS as adjuvant therapy versus observation – 29 months versus 14 months – in these patients AMBASSADOR /KEYNOTE-123 is the first positive trial for KEYTRUDA as adjuvant.

United statesMerck co incAlliance for clinical trials in oncologyDevelopment agreementStatement of merck co incMerck research laboratoriesNational cancer instituteExchange commissionNational clinical trials network groupsGenitourinary malignancies branchNational institutes of healthAmerican society of clinical oncologyClinical oncologyCancers symposiumAndrea apoloBladder cancer section

Merck s KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Muscle-Invasive Urothelial Carcinoma (MIUC) After Surgery

Merck s KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Muscle-Invasive Urothelial Carcinoma (MIUC) After Surgery
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesPeter dannenbaumDamini chokshiJulie cunninghamChrissy trankAlliance for clinical trials in oncologyNational clinical trials network groupsNational institutes of healthUs national cancer instituteDevelopment agreementExchange commissionData monitoring committeeStatement of merck co incMerck research laboratoriesMerck co incMarjorie green

Merck (MRK) KEYTRUDA Met Primary Endpoint of DFS in Certain Patients With MIUC After Surgery

Merck (MRK) KEYTRUDA Met Primary Endpoint of DFS in Certain Patients With MIUC After Surgery
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesMerck research laboratoriesNational institutes of healthDevelopment agreementNational clinical trials network groupsAlliance for clinical trials in oncologyUs national cancer instituteData monitoring committeeMarjorie greenMerck researchCancer instituteNational institutesClinical trialsNational clinical trials networkCooperative researchBacillus calmette guerin unresponsive

Merck s KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Muscle-Invasive Urothelial Carcinoma (MIUC) After Surgery | Region

RAHWAY, N.J. (BUSINESS WIRE) Oct 5, 2023

United statesPeter dannenbaumJulie cunninghamChrissy trankDamini chokshiStatement of merck co incData monitoring committeeAlliance for clinical trials in oncologyNational institutes of healthUs national cancer instituteExchange commissionMerck research laboratoriesMerck co incNational clinical trials network groupsDevelopment agreementMarjorie green